Brief: Relief Therapeutics Releases 60-Day Results From Phase 2B/3 Clinical Trial Of Intravenous RLF-100

MindMaze Therapeutics Holding SA

30/03/2021 06:13

March 30 (Reuters) - RELIEF THERAPEUTICS Holding SA
 RLFB.S :
    * CONFIRMS PUBLICATION OF 60-DAY RESULTS FROM PHASE 2B / 3
CLINICAL TRIAL OF INTRAVENOUS RLF-100 ™ (AVIPTADIL)
    * ACCORDING TO NEURORX, RLF-100 ™ MET THE PRIMARY ENDPOINT
FOR
SUCCESSFUL RECOVERY FROM RESPIRATORY FAILURE ACROSS ALL PATIENTS
AND LOCATIONS ON DAY 28 (P = 0.014) AND DAY 60 (P = 0.013)
    * RLF-100 SHOWED A SIGNIFICANT SURVIVAL BENEFIT (P = <0.001)
)
AFTER ADAPTING THE VENTILATION STATUS AND THE TEST CENTER.

Source text - https://bit.ly/3sA8ccd
Further company coverage:  RLFB.S 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))